Core Viewpoint - Voyager Acquisition Corporation announced that holders of 25,217,315 Class A ordinary shares redeemed approximately 99.67% of the total Class A shares outstanding in connection with the completion of its business combination with VERAXA Biotech AG, leaving approximately $885,556 in the trust account and converting 82,685 Class A shares into shares of VERAXA Biotech Holding AG [1] Group 1: Business Combination Details - The Business Combination Agreement between Voyager and VERAXA was entered into on April 22, 2025, and upon closing, the combined company is expected to be publicly traded on NASDAQ under the symbol "VRXA" [2] - Following the completion of the Business Combination, the majority of Class A shares were redeemed, indicating a significant shareholder exit prior to the merger [1] Group 2: Company Profiles - VERAXA Biotech AG focuses on the discovery and development of next-generation antibody-based therapeutics, including bispecific ADCs and T cell engagers, leveraging transformative technologies and quality-by-design principles [3] - Voyager Acquisition Corporation is a special purpose acquisition company aiming to revolutionize the healthcare sector through strategic mergers and business combinations, supported by a team with extensive expertise in investing and medical innovation [5]
Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG